The gospel of lung cancer patients! Lilly's classic anti-tumor drug, Lithane, is 30% lower than that of

According to industry sources, from July 2019, Lilly Pharmaceuticals will reduce the price of its classic anti-tumor drug Libita
®
(injection of pemequaldd dodium), a reduction of about 30%, the actual decline may vary slightly from place to place based on prices.
malignant tumor has become one of the leading causes of death among chinese residents, and in malignant tumors, the incidence and mortality rate of lung cancer are the highest. According to the latest data released by the National Cancer Center, in 2015, there were about 787,000 new lung cancer patients in China, and about 631,000 deaths from lung cancer. Among them, non-small cell lung cancer accounts for 80%-85% of all lung cancer patients, is the most common type of lung cancer.More than 80% of lung cancer patients
were explicitly diagnosed in the middle and late stage (Phase IIIb-IV), chemotherapy is the main treatment for patients with metastatic non-small cell lung cancer withno-driven gene mutations, no targeted treatment options, or patients with poor immunotherapy after treatment.
, a new multi-target anti-metabolic drug developed by Lilly Pharmaceuticals, is a structure containing anti-folic acid preparations with core pyrophileine groups, which inhibits the growth of tumor cells by destroying the normal metabolic process of folate dependence in cells, thereby inhibiting tumor growth.
, a classic chemotherapy drug for Lilly, has helped more than 60,000 patients since its successful launch in China in 2005. Libitai was officially listed in China in December 2005 and has been approved by the State Administration of Food and Drug Administration for the treatment of malignant pleural mesothelioma. In June 2011, it was approved for "secondary and maintenance therapy for advanced or metastatic non-small cell lung cancer." In June 2014, it was approved for use in locallate or metastatic non-small cell lung cancer and continued to maintain the treatment of new indications.
compared with traditional chemotherapy drugs, Libita has "efficient, low-toxic" characteristics, not only can significantly prolong the lives of non-scale cancer lung cancer patients, but also lower toxicity, patients are more easily tolerated. Registered clinical JMIL in China and the world-renowned JMDB and PARAMOUNT clinical studies have shown that Libita's first-line and continuing treatment significantly prolongs the total survival of non-scale cancer patients.Prior to
, Libitai's Shanghai Sunshine Sourplatform was priced at RMB 9176.27 and RMB 2676.58 in the 500mg specification. Lilly this round of downward prices than Tai, the follow-up will be in line with the bidding process around the gradual implementation. The price reduction can be said to be one of the concrete actions to support the implementation of the national "4 plus 7" city drug collection policy, but also further reduce the financial burden of cancer on the families and society of patients, so that more patients have access to high-quality primary medicine.
References:
1015 China's Malignant Tumor Epidemic Analysis. (J). Chinese Journal of Oncology. 2019, 41 (1)
2'D'addario G, Fruh M, Reck M, et al. Metastatic-Small-Cell Lung Cancer: ESMO Clinical Practice. Ann 0ncol, 2010, 21 (8): 116-119. doi: 10.1093/annonc/mdq189
3: Libita ® approved for advanced non-squamous non-small cell lung cancer and continue to be treated. Chinese Cancer Journal. Issue
2014.